Join

Compare · ILMN vs QGEN

ILMN vs QGEN

Side-by-side comparison of Illumina Inc. (ILMN) and Qiagen N.V. (QGEN): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. ILMN focuses on Medical Specialities, while QGEN focuses on Biotechnology: Biological Products (No Diagnostic Substances).
  • ILMN is the larger of the two at $20.63B, about 2.9x QGEN ($7.06B).
  • Over the past year, ILMN is up 74.3% and QGEN is down 20.6% - ILMN leads by 94.9 points.
  • ILMN has been more active in the news (7 items in the past 4 weeks vs 5 for QGEN).
  • ILMN has more recent analyst coverage (25 ratings vs 23 for QGEN).
PerformanceILMN+74.30%QGEN-20.62%
2025-05-02+0.00%2026-05-01
MetricILMNQGEN
Company
Illumina Inc.
Qiagen N.V.
Price
$135.72+7.16%
$34.24-1.01%
Market cap
$20.63B
$7.06B
1M return
+7.12%
-15.16%
1Y return
+74.30%
-20.62%
Industry
Medical Specialities
Biotechnology: Biological Products (No Diagnostic Substances)
Exchange
NASDAQ
NYSE
IPO
2000
2026
News (4w)
7
5
Recent ratings
25
23
ILMN

Illumina Inc.

Illumina, Inc. provides sequencing and array-based solutions for genetic and genomic analysis. Its products and services serve customers in a range of markets enabling the adoption of genomic solutions in research and clinical settings for applications in the life sciences, oncology, reproductive health, agriculture, and other emerging segments. The company provides instruments and consumables used in genetic analysis; and genotyping and sequencing services, instrument service contracts, and development and licensing agreements. Its customers include genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. The company markets and distributes its products directly to customers in North America, Europe, Latin America, and the Asia-Pacific region, as well as sells through life-science distributors in various markets within Europe, the Asia-Pacific region, Latin America, the Middle East, and Africa. It has a collaboration agreement with Geneseeq Technology Inc. to develop comprehensive in-vitro diagnostic (IVD) NGS testing kits for cancer. The company was incorporated in 1998 and is headquartered in San Diego, California.

QGEN

Qiagen N.V.

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc., as well as a strategic alliance agreement with Sysmex Corporation. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Latest ILMN

Latest QGEN